National Cancer Institute Drug Dictionary - description

Actice Clinical Trials (NCI)

Closed Clinical Trials (NCI)

Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib

Memorial Sloan-Kettering Cancer Center on kinase inhibitors

Overview article on kinase inhibitors by Italian National Cancer Institute - published in Journal of Clinical Pharmacology

Chronic Myelogenous Leukemia treatment - National Cancer Institute

M.D. Anderson on leukemia treatment

Leukemia and Lymphoma Society

Bosutinib: A Novel Second-Generation Tyrosine Kinase Inhibitor

Valproic acid (VPA) is a HDAC inhibitor recently identified as a potential anticancer drug. Italian researchers found that a combination of VPA and bosutinib could kill colon cancer cells in the laboratory. They concluded the two drugs could be used together clinically in the future.

Overview from Department of Hematology and Oncology, University Hospital Aachen, Germany